Natalizumab therapy of multiple sclerosis: Recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society

A. Ghezzi, L. M E Grimaldi, M. G. Marrosu, C. Pozzilli, G. Comi, A. Bertolotto, M. Trojano, P. Gallo, R. Capra, D. Centonze, E. Millefiorini, S. Sotgiu, V. Brescia Morra, M. P. Amato, A. Lugaresi, G. Mancardi, D. Caputo, E. Montanari, L. Provinciali, L. DurelliR. Bergamaschi, P. Bellantonio, M. R. Tola, S. Cottone, G. Savettieri, G. Tedeschi

Research output: Contribution to journalArticlepeer-review

Abstract

Three years after the introduction of natalizumab (NA) therapy for the second line treatment of relapsing-remitting multiple sclerosis (MS), Italian MS centers critically reviewed the scientific literature and their own clinical experience. Natalizumab was shown to be highly efficaciuos in the treatment of MS. However, the risk of progressive multifocal leukoencephalopathy was confirmed and defined better. This article summarizes the MS-SIN Study Group recommendations on the use of NA in MS, with particular reference to the appropriate selection and monitoring of patients as well as to the management of adverse events.

Original languageEnglish
Pages (from-to)351-358
Number of pages8
JournalNeurological Sciences
Volume32
Issue number2
DOIs
Publication statusPublished - Apr 2011

Keywords

  • IRIS
  • Multiple sclerosis
  • Natalizumab
  • PML

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Dermatology

Fingerprint Dive into the research topics of 'Natalizumab therapy of multiple sclerosis: Recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society'. Together they form a unique fingerprint.

Cite this